drugset / Trial / NCT02063386

AZD1722 Open Label, Absorption Distribution Metabolism and Excretion Study

NCT02063386

Phase 1 Completed 26 enrolled Ardelyx
Non-randomizedSingle-groupOpen-labelBasic science

Summary

To assess the absorption, distribution, metabolism and excretion of a single dose of 14C labelled AZD1722 in order to define the rates and routes of elimination of AZD1722 and if formed, metabolites.

Timeline

Start
2014-04
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Tenapanor Small molecule 15 mg Oral

Indications

No indication recorded.